Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methylprednisolone
Drug ID BADD_D01433
Description Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone].[A188811] It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957.[L10785] In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression.[A192813] The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials.[L12666]
Indications and Usage Oral and intramuscular methylprednisolone are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, nervous system, and other disorders.[L10785,L10788] Intra-articular and soft tissue injections are indicated for short term treatment of acute gouty arthritis, acute and subactute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, and synovitis of osteoarthritis.[L10788] Intralesional injections are indicated for alopecia areata, discoid lupus erythematosus, keloids, lichen planus, lichen simplex chronicus and psoriatic plaques, necrobiosis lipoidica diabeticorum, and localized hypertrophic infiltrated inflammatory lesions of granuloma annulare.[L10788]
Marketing Status approved; vet_approved
ATC Code D07AA01; D10AA02; H02AB04
DrugBank ID DB00959
KEGG ID D00407
MeSH ID D008775
PubChem ID 6741
TTD Drug ID D08PIQ
NDC Product Code 72647-331; 0781-5022; 80425-0230; 59746-003; 59762-0049; 63187-160; 71205-453; 0603-4593; 82094-402; 60722-1003; 64958-0084; 55289-649; 59762-4440; 63629-2218; 68001-557; 68001-560; 80425-0242; 22552-0029; 0009-0056; 45865-104; 59762-0050; 59762-0051; 60760-373; 63187-802; 65162-871; 68071-5221; 70121-1000; 59746-015; 65162-982; 68001-005; 68071-4028; 68084-149; 68788-4593; 71205-054; 72189-264; 82094-401; 45865-417; 50090-3094; 59746-002; 63629-2433; 68001-558; 68180-686; 69306-400; 70518-3622; 82094-403; 59746-001; 68071-2301; 68180-687; 70518-2982; 70771-1348; 70771-1349; 80425-0255; 0009-0073; 49999-153; 53002-3120; 63629-2226; 68001-559; 68180-685; 68180-688; 68382-917; 68382-918; 68382-919; 70771-1350; 80425-0231; 0904-6914; 49452-4686; 51552-0603; 0009-0020; 42806-400; 65162-984; 68180-689; 68382-916; 68788-8276; 69306-004; 70121-1001; 70771-1351; 76420-041; 82298-118; 76420-193; 82094-404; 82094-405; 51927-0201; 0009-0022; 65162-980; 68071-2745; 68788-7833; 0009-0038; 57582-011; 0009-0176; 57582-101
UNII X4W7ZR7023
Synonyms Methylprednisolone | Metipred | 6-Methylprednisolone | 6 Methylprednisolone | Urbason | Medrol
Chemical Information
Molecular Formula C22H30O5
CAS Registry Number 83-43-2
SMILES CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tendonitis12.01.07.007; 15.07.01.0030.000048%Not Available
Tenosynovitis15.07.01.0040.000080%Not Available
Tension19.06.02.0050.000032%Not Available
Tetany15.05.03.013; 14.04.01.005; 05.04.02.0030.000048%Not Available
Therapeutic response unexpected08.06.01.0010.000195%Not Available
Throat irritation22.12.03.029; 07.05.05.0370.000064%Not Available
Throat tightness22.12.03.031; 19.01.02.0050.000214%Not Available
Thrombocytopenia01.08.01.0020.000352%Not Available
Thrombocytosis01.08.02.0010.000048%Not Available
Thrombophlebitis24.01.02.0010.000064%Not Available
Thrombotic microangiopathy24.01.01.013; 20.01.07.004; 01.01.02.0060.000032%Not Available
Thyroid disorder05.02.01.0020.000048%Not Available
Tic19.11.04.001; 17.02.05.0240.000064%Not Available
Tinnitus17.04.07.004; 04.04.01.0020.000134%
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.0070.000032%Not Available
Toxic encephalopathy17.13.01.004; 12.03.01.0270.000048%Not Available
Transient ischaemic attack24.04.06.005; 17.08.04.0010.000096%
Transplant rejection12.02.05.022; 10.02.03.0020.000160%Not Available
Transverse sinus thrombosis24.01.04.013; 17.08.03.0040.000032%Not Available
Tremor17.01.06.0020.000396%
Tumour lysis syndrome14.05.01.004; 16.32.03.0020.000192%
Type I hypersensitivity10.01.03.0060.000096%Not Available
Unresponsive to stimuli17.02.05.031--Not Available
Upper gastrointestinal haemorrhage24.07.02.024; 07.12.02.0060.000176%
Urinary incontinence20.02.02.010; 17.05.01.0080.000128%
Urinary retention20.02.02.0110.000160%
Urticaria23.04.02.001; 10.01.06.0010.001758%
Vasculitis24.12.04.027; 10.02.02.0060.000080%
Ventricular fibrillation02.03.04.0080.000048%
Ventricular tachycardia02.03.04.010--
The 16th Page    First    Pre   16 17 18 19 20    Next   Last    Total 22 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene